US EditionPublished • loading... • Updated
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
Summary by TBNweekly
34 Articles
34 Articles
Bennington Banner+33 Reposted by 33 other sources
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors
Coverage Details
Total News Sources34
Leaning Left3Leaning Right5Center10Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 17%
C 55%
R 28%
Factuality
To view factuality data please Upgrade to Premium
